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Colony stimulating factor (CSF-1) and its receptor, CSF-1R, have been previously well studied in humans
and rodents to dissect the role they play in development of cells of the mononuclear phagocyte system. A
second ligand for the CSF-1R, IL-34 has been described in several species. In this study, we have cloned
and expressed the feline CSF-1R and examined the responsiveness to CSF-1 and IL-34 from a range of spe-
cies. The results indicate that pig and human CSF-1 and human IL-34 are equally effective in cats, where
both mouse CSF-1 and IL-34 are signiﬁcantly less active. Recombinant human CSF-1 can be used to gen-
erate populations of feline bone marrow and monocyte derived macrophages that can be used to further
dissect macrophage-speciﬁc gene expression in this species, and to compare it to data derived from
mouse, human and pig. These results set the scene for therapeutic use of CSF-1 and IL-34 in cats.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
Macrophage colony-stimulating factor (CSF-1) controls the pro-
liferation and differentiation of cells of the mononuclear phagocyte
lineage [1–3]. The receptor for CSF-1 (CSF-1R, MCSFR, CD115 or
FMS) is expressed in all cells of the mononuclear phagocyte lineage
including progenitor cells, osteoclasts and dendritic cells [4]. CSF-
1R is the proto-oncogene form of the transforming gene of Feline
McDonough Sarcoma (SM-FeSV), hence its name FMS [5]. A second
ligand for the CSF-1R was ﬁrst described in humans [6] and subse-
quent studies conﬁrmed that the two-ligand, one-receptor, system
is conserved in birds [7]. Binding of either ligand to the CSF-1R pro-
duces receptor dimerization, auto-phosphorylation, activation of
down-stream signalling (ERK1/2, Akt) and expression of genes in-
volved in survival and proliferation of the mononuclear phagocyte
lineage cells [6,8–10].
Human CSF-1 cDNAwas cloned and expressed in the 1980s, and
when injected into mice, it promoted an increase in blood mono-
cyte and tissue macrophage numbers [11]. Human CSF-1 is almost
as effective as mouse CSF-1 in stimulating mouse macrophage pro-
liferation in vitro [12,13] and indeed is equally active on all mam-
malian species tested (mouse, cat, sheep, dog, and pig). Conversely,
mouse CSF-1 bioactivity is restricted to non-primate species
[2,7,14–18]. IL-34 has even more restricted species cross-reactivity;Hume).
 license.with the human and mouse ligands much less active on the other
species, although both were active on the pig CSF-1R [2]. CSF-1 has
been widely-used to drive proliferation and differentiation of
mature macrophages from bone marrow or blood monocyte
progenitors in multiple species. In general, CSF-1 stimulated cells
are driven towards a more immunosuppressive function [1,19],
where another colony-stimulating factor, GM-CSF or CSF-2,
drives differentiation of phagocytic cells with antigen-presenting
function [20,21]. GM-CSF has been used to produce antigen pre-
senting cells (APCs) from feline bone marrow [22–24], but there
are no reports of using CSF-1 to generate feline monocyte derived
macrophages.
Recombinant colony stimulating factors and/or antibodies di-
rected against the ligand or the receptor have been tested in a
range of animal models and human patients [1,25–27]. Macro-
phages play an important role in tissue repair in a number of tis-
sues including kidney, liver, heart, brain and lung [28–32] and
CSF-1 administration has been shown to promote regeneration in
a number of models. For example, in ischaemia reperfusion in
mice, a model of acute renal injury, recombinant human CSF-1
administration was able to stimulate macrophage inﬁltration to
promote epithelial repair and to prevent interstitial ﬁbrosis [33].
Acute renal failure in cats can arise from numerous causes [34–
40] and has a very poor prognosis [36,41]. Many cats who survive
to discharge are azotaemic and, as a result, are likely to have high
morbidity and greatly-reduced lifespan, while a second ‘‘wave’’ of
apoptosis seems to occur in the recovery phase which may limit
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that CSF-1 could have a therapeutic beneﬁt in cats with acute renal
injury. For this purpose, we need to knowwhether it would be nec-
essary to produce feline-speciﬁc agents. In the present study, we
have produced a cat CSF-1R-expressing factor-dependent cell line
and evaluated responsiveness of the cat receptor to CSF-1 and IL-
34 from multiple species.2. Materials and methods
2.1. Cell culture and reagents
The Ba/F3 cell line, transfected Ba/F3 cells and primary bone
marrow cells were cultured in RPMI 1640 medium (Sigma) con-
taining 10% HI-FCS, 2 mM L-glutamine, 100 lg/ml streptomycin,
and 100 Units/ml penicillin. Untransfected Ba/F3 cells were main-
tained in medium containing 10% IL-3 from X63 Ag8-653 myeloma
cells carrying an expression vector for IL-3 [43,44]. Unless other-
wise stated, transfected Ba/F3 cells were maintained in medium
containing 104 Units/ml rhCSF-1 (a gift from Chiron Corp., Emery-
ville, CA, USA). Both Ba/F3 cells and primary bone marrow cells
(BMCs) were incubated at 37 C with 5% CO2.2.2. Total RNA extraction and cDNA synthesis
With owner’s consent, tissues were collected from a 5-year-old
male Siamese cat that was being euthanized for medical reasons.
Tissues were placed immediately in RNA Later (QIAGEN) and
stored at room temperature for 24 h until RNA extraction was per-
formed. RNA was extracted from skin, testes, sub-mandibular
lymph node, uterus and spleen. Total RNA was prepared using an
RNeasy kit (QIAGEN) according to the manufacturer’s instructions,
including a DNase digestion step. Feline-speciﬁc cDNA was pro-
duced using 1 lg of total RNA and reversed transcribed using Im-
Prom-II (Promega). Successful cDNA production without genomic
DNA contamination was demonstrated using feline HPRT primers
(Table 1) [45].2.3. Expression cloning of feline CSF-1R
Feline PCR primer pairs (Table 1) were designed for ampliﬁca-
tion of full-length CSF-1R from the incomplete published feline
CSF-1R cDNA sequence (Ensembl ENSFCAP00000003348). Ampliﬁ-
cation was achieved using feline cDNA and expand high-ﬁdelity
enzyme (Roche) with 3 mM MgCl2 using an initial cycle of 94 C
for 3 min followed by 35 cycles of 94 C for 30 s, 60 C for 30 s
72 C for 3 min and one cycle of 72 C for 10 min. PCR products
were gel puriﬁed using a QIAquick gel extraction kit (QIAGEN)
and cloned in frame with V5-His C-terminal tag of pEF6/V5-His
expression construct using TOPO cloning kit (Invitrogen). DNA
sequencing was performed by DNA Sequencing and Services
(MRCPPU, College of Life Sciences, University of Dundee, Scotland,
www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver. 3.1Table 1
Table of primers used for production of feline cDNA and cloning of feline CSF-1R. A
kozak sequence (highlighted in bold) was included in CSF-1R forward primer for
optimal translation initiation. Feline HRPT primers from Penning et al. [45].
Primer name Primer sequence 50–30 Tm
(C)
Size
(bp)
Feline HPRT Forward ACTGTAATGACCAGTCAACAGGGG 60.0 210
Feline HPRT Reverse TGTATCCAACACTTCGAGGAGTCC 60.0 –
Feline CSF-1R Forward GCC ATG GGC CCA AGG GCT 61.5 2946
Feline CSF-1R Reverse GCA GAA CTG GTA GTT GTT GGG CTG 61.9 –chemistry on an Applied Biosystems model 3730 automated capil-
lary DNA sequence.
2.4. Generation of stable cell lines
For generation of stable Ba/F3 cells expressing feline CSF-1R,
5  106 Ba/F3 cells were electroporated (300 V, 975 lF) with
10 lg DNA (pEF6_fCSF-1R or empty pEF6 DNA), and selected with
30 lg/ml blasticidin (Invitrogen) and 10% IL-3 for 6 days prior to
further selection with 30 lg/ml blasticidin and 104 Units/ml of
rhCSF-1.
2.5. Immunoblotting
Whole-cell lysate was prepared by lysing 0.5  106 cells in
10 mM Tris containing 2% SDS and boiling for 10 min at 100 C.
Protein concentration was determined using DC protein assay
(Bio-Rad) with 10 lg of protein mixed with Laemmli buffer (Invit-
rogen) and 5 mM DTT. Samples were run on a 4–12% gradient pre-
cast SDS–PAGE gel (Bio-Rad) and transferred onto polyvinylidene
diﬂuoride membrane, as per manufacturer’s directions (Bio-Rad).
The membrane was blocked with 5% skimmed milk powder in
TBS-Tween 20 at 4 C overnight prior to being washed and probed
with 1:5000 dilution of mouse anti-v5 tag antibody (AbD Serotec
MCA1360G) and 1:5000 dilution of anti-mouse IgG HRP conju-
gated antibody (Cell Signalling Technology, 7076) and detected
using enhanced chemiluminescence (ECL) reagents (Amersham,
GE Healthcare, UK).
2.6. Isolation of feline peripheral blood mononuclear (PBMC) and bone
marrow cells (BMC)
A 6-year-old male neutered domestic short-haired cat was
euthanized by pentobarbitone for medical reasons and owner’s
consent obtained to collect 20 ml of blood and one femur. The fe-
mur was dissected, placed in a zip-lock bag and placed on ice.
20 ml of blood was collected into a syringe containing Acid-cit-
rate-dextroseat 1:10 dilution and placed on ice following collec-
tion. For BMC collection, both the proximal and distal ends of the
femur were removed and using an 18 g needle, cells were ﬂushed
with 10 ml RPMI (Sigma) containing 5 mM EDTA to prevent clot-
ting. Cells were washed and re-suspended in red cell lysis buffer
(Bio Legend, San Diego, CA) for 5 min, followed by a further 2
washes in PBS. Feline PBMC were isolated using Lymphoprep
(Axis-Shield, Oslo, Norway) following manufacturer’s instructions,
including the addition of red cell lysis buffer as above.
2.7. Feline peripheral PBMC and BMC stimulation with recombinant
human CSF-1
Ten million PBMC and BMC were cultured in 60 mm bacterio-
logical plates with 4 ml RPMI supplemented with 104 Units/ml
rhCSF-1, and incubated for 8 days at 37 C, 5% CO2.
2.8. Preparation of cells for cytospin
After 8 days in culture, adherent cells from both blood and BMC
cultures were recovered by repeated ﬂushing of medium over the
bottom of the culture dish until all adherent cells were removed.
Cells were counted and 0.5  106 cell/ml were collected with
100 ll of cell suspension placed into the cytospin chamber
(Thermo) and centrifuged at 300 rpm for 3 min. Slides were
air-dried and ﬁxed in 100% methanol for 5 min prior to staining
with Leishman’s stain (Sigma L6254) for the identiﬁcation of mac-
rophage nuclei. Cytospins were examined under 20 magniﬁca-
tion for cellular morphology.
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Following harvest of day 8 adherent cells from both blood and
BMC cultures (as above), 1  106 cells/ml were plated/well of a 6-
well plate in duplicate and cultured overnight at 37 C, 5% CO2.
Phagocytosis was initiated by the addition of FITC conjugated
Zymosan bio-particles (Molecular Probes) at a particle:cell ratio
of 10:1, followed by further incubation for 1 h. Phagocytosis was
stopped by the addition of 500 ll/well of ice-cold PBS, followed
by 2 PBS washes. Cells were analysed for Zymosan particle uptake
using ﬂuorescence microscopy (Zeiss LSM710).
2.10. Cell viability assays
Stable Ba/F3 cells expressing feline CSF-1R were maintained in
culture with RPMI supplemented with 104 Units/ml rhCSF-1 prior
to MTT assay. 2  104 cells/well were plated in quadruplicate and
appropriate treatment (serial dilutions of rhCSF-1, rpCSF-1,
rmCSF-1, (R&D Systems 416-ML), rhIL-34 (R&D Systems 5265), or
rmIL-34 (R&D Systems 5195) added to make a total volume of
100 ll per well. Cells were incubated for 48 h at 37 C, 5% CO2, after
which 10 ll of MTT (Sigma–Aldrich M5655) was added directly to
each well (ﬁnal concentration of 0.5 mg/ml) and incubated at 37 C
for 3 h prior to solubilisation with 100 ll of solubilisation agent
(0.1 M HCl, 10% Triton x-100 and isopropanol) and overnight incu-
bation. Plates were read at 570 nm with reference wavelength of
405 nm.
2.11. 3D modelling of contact amino acids
3D models in PDB format were generated with 3D-Jigsaw
(http://bmmcancerresearchuk.org/3djigsaw/) using structure-
based alignments (performed by Domain Fishing). 3D models of
human CSF-1R (PDB 4DKD) and mouse CSF-1R (PDB 4EXP), were
obtained and viewed in FirstGlance in Jmol (http://ﬁrstg-
lance.jmol.org). The 3Dmodel of feline CSF-1R was generated using
3D-Jigsaw with the mouse CSF-1R structure as template (3EJJ).
Non-conserved contact amino acids for IL-34 and CSF-1 binding
of the CSF-1R were identiﬁed using recently-published data [46–
48] and highlighted.3. Results
3.1. Cloning of feline CSF-1R
Woolford et al. [14] previously cloned feline CSF-1R cDNA from
splenic cDNA template but we identiﬁed a greater abundance of
CSF-1R cDNA using the lymph node template. Agarose gel electro-
phoresis of the PCR products revealed the expected single band of
approximately 3000 base pairs in this tissue. Following gel puriﬁ-
cation, feline CSF-1R was successfully cloned in frame with V5-
His C-terminal tag of pEF6 V5-His TOPO plasmid. The cDNA and
protein sequences were conﬁrmed and multiple species align-
ments of CSF-1R performed (Fig. 1). The feline CSF-1R extracellular
domain shares 88% homology with the canine CSF-1R, 83% homol-
ogy with human CSF-1R, and 75% with the mouse CSF-1R, while fe-
line and pig share 80% homology. The cloned feline CSF-1R encodes
the full-length receptor of 982 amino acids, including a 19 amino
acid signal peptide (Met1 – Gly19) and a 963 amino acid mature
chain (Val20 to Cys982). The sequence is identical to the previ-
ously-published feline CSF-1R [14]. The earlier study emphasised
variation between feline c-fms and the transforming genes of the
feline sarcoma virus, v-fms.
The availability of the crystal structure for the human CSF-1/IL-
34 complexes with CSF-1R permits a structure-based modelling ofthe same complexes in other species. The contact residues for the
ligands are not conserved across species. The human and feline
CSF-1R binding sites for CSF-1 and IL-34 differ by 7 non-conserved
amino acids (Fig. 2A and B). Similarly, there are 10 contact amino
acid differences between mouse and feline CSF-1R for the CSF-1
and IL-34 binding sites (Fig. 2C and D). As noted previously in an
analysis of pig CSF-1R [2], it is difﬁcult to predict from these
changes whether the cat receptor will bind CSF-1 or IL-34 from
other species, and the results may inform both therapeutic applica-
tions and structure–function predictions.
3.2. Production of feline CSF-1R expressing cells
To enable studies of the cat CSF-1R binding speciﬁcity, we sta-
bly transfected the IL-3 dependent Ba/F3 cell line as previously de-
scribed for the human, chicken and pig receptors with full-length
feline CSF-1R [2,7,49]. Stable clones were initially selected for their
survival in blasticidin, followed by further selection in rhCSF-1. The
presence of feline CSF-1R in Ba/F3 cells (Ba/F3fCSF-1R) permitted
proliferation in response to rhCSF-1 and removed the dependence
of these cells for IL-3. Western blot analysis of these cells demon-
strated detectable expression of feline CSF-1R at a similar level to
porcine CSF-1R expressed in Ba/F3 cells [2] (Fig. 3).
3.3. Activation of feline CSF-1R with human, mouse and porcine CSF-1
The MTT bioassay for assessing the response of transfected Ba/
F3 cells to CSF-1 has been previously described and optimised [2].
Both the parent Ba/F3 and Ba/F3 cells expressing feline CSF-1R sur-
vived and proliferated in IL-3. Human, mouse and porcine recom-
binant CSF-1 allowed the Ba/F3 cells expressing feline CSF-1R to
survive, but with distinct efﬁcacy. The actual EC50 differs between
experiments. Because the cells consume the factor, the assay is
sensitive to precise cell number and duration. In a side-by-side
comparison, mouse CSF-1 was substantially less active than human
CSF-1 (Fig. 4A) whereas human and pig CSF-1 demonstrated virtu-
ally identical activity on the feline CSF-1R (Fig. 4B), comparable to
their reported activity on the pig CSF-1R [2].
3.4. Cultivation of feline bone marrow and peripheral blood
mononuclear cells with human CSF-1
We have previously reported the production of bone marrow-
derived macrophages from pig marrow using human CSF-1 [50].
Similar to that study’s ﬁndings, feline BMC and PBMC cultivated
in recombinant human CSF-1 increased in number, granularity,
and size, and became adherent over an 8 day period, demonstrat-
ing clear macrophage-like morphology (Fig. 5A and B). Cells not
cultured with CSF-1 did not adhere, grow or survive. This was par-
ticularly evident for the bone marrow-derived-macrophages
(Fig. 5C and D). Both macrophage populations of primary cell pop-
ulations were potently phagocytic and ingested particles after one
hour of incubation (Fig. 6). This result demonstrates that feline
CSF-1R in its native context is able to bind and respond to recom-
binant human CSF-1. By analogy to our previous study on the pig,
this method would allow the freezing of marrow progenitors from
euthanized cats for multiple future studies in vitro.
3.5. Activation of feline CSF-1R with IL-34
Human and mouse IL-34 have similar activity on the pig CSF-1R
[2]. Using the MTT bioassay with Ba/F3 cells expressing feline
CSF-1R, both human and mouse IL-34 were able to bind and acti-
vate the feline CSF-1R, in a dose-dependent manner (Fig. 7), but
the EC50 for mouse IL-34 on the feline CSF-1R was approximately
threefold higher than for human IL-34. Neither human, nor mouse
Fig. 1. Alignment of cloned feline CSF-1R extracellular domain with human, pig and mouse. Alignment was performed using Clustal W (http://www.ebi.ac.uk/Tools/msa/
clustalw2/). The alignment clearly demonstrates the high level of homology that exists in the CSF-1R extracellular domain containing the IL-34 and CSF-1 binding sites. Of
particular note is the high level of homology between both the feline and canine CSF-1R (88%) and feline and human CSF-1R (83%) while the homology between feline and the
mouse and pig CSF-1R share 75%and 80% homology respectively. The red colour represents small hydrophobic amino acids, blue colour represents acidic amino acids,
magenta denotes basic amino acids, and the green colour corresponds to hydrophilic or polar amino acids. Identical amino acids are represented by ‘‘⁄’’, conserved
substitutions are represented by ‘‘:’’ and semi-conserved substitutions are represented by ‘‘.’’.
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Fig. 2. 3D models of non-conserved CSF-1 and IL-34 contact amino acids between human, mouse and cat CSF-1R. 3D models demonstrating the charged amino acid changes
between human (A) and cat (B) CSF-1R and between mouse (C) and cat (D) CSF-1R. Models were generated using the PDB ﬁles for mouse CSF-1R (3EJJ) and human CSF-1R
(4DKD chain X). The mouse PDB ﬁle (3EJJ) was used as a template to generate the cat CSF-1R. Published contact amino acids for both human and mouse CSF-1R binding sites
for CSF-1 and IL-34 were analysed and non-conserved contact amino acids highlighted using FirstGlance (http://ﬁrstglance.jmol.org). Non-conserved amino acids for CSF-1
binding are represented by black numbers; red numbers indicate CSF-1 and IL-34 binding, while blue numbers indicates IL-34 binding. Positively charged atoms are
represented by blue colour and negatively charged atoms by red colour. Medium blue coloured atoms denote partially charged atoms.
Fig. 3. Western blot of transfected Ba/F3 cells expressing feline CSF-1R. A western
blot was performed on Ba/F3 cells expressing feline CSF-1R. Cells were cultured in
rhCSF-1 prior to collection of cell lysate. Cell lysate was collected from both Ba/F3
cells transfected with feline CSF-1R, but also Ba/F3 cell transfected with empty pEF6
vector as a negative control. A band at 150 kDa, corresponding to the predicted size
is clearly visible for the feline CSF-1R, with no band identiﬁed for the negative
control.
634 D.J. Gow et al. / Cytokine 61 (2013) 630–638recombinant IL-34 was as active as human CSF-1 under the same
conditions (Fig. 8).4. Discussion
We conﬁrmed the published cDNA and protein sequence of fe-
line CSF-1R and stably cloned the cat receptor into the Ba/F3 cell
line. Activation of feline CSF-1R by recombinant human CSF-1
was previously tested by Woolford et al. [14]. Expression of onco-
genic forms of feline CSF-1R in Rat-2 cells, which ordinarily are un-
able to grow in soft agar [51], permitted the formation of colonies
in soft agar upon the addition of human CSF-1 [14]. However, the
native receptor was insufﬁcient to cause transformation even in
the presence of human CSF-1. This study also gave no insight into
relative efﬁcacy. In the current study, the addition of either human
or mouse CSF-1 to Ba/F3 cells expressing full length feline CSF-1R
produced survival and proliferation of cells that are dependent
on CSF-1 for survival. Mouse CSF-1 was substantially less active
on the feline receptor than human CSF-1. In this respect, the cat
CSF-1R is idiosyncratic compared to the other species tested.
Mouse and pig CSF-1R respond equally to mouse, pig and human
CSF-1, human CSF-1R responds to human and pig, but not to mouse
CSF-1 [2].
Publication of the mouse CSF-1: CSF-1R contact amino acids
[48] permits a structure-based analysis of receptor speciﬁcity.
There are 6 non-conserved contact amino acids (His6, Asn13,
Phe55, Glu78, Arg79, and Asn85 in mouse) between mouse and
Fig. 4. Activity of human, mouse and porcine recombinant CSF-1 on feline CSF-1R expressed in Ba/F3 cells. An MTT cell viability assay was used to assess the biological
activity of recombinant human, mouse and porcine CSF-1 in the feline CSF-1R. (A) Both human and mouse CSF-1 are biologically active on the feline CSF-1R, with mouse CSF-1
demonstrating reduced activity compared to human CSF-1. (B) Comparing the effects of human and porcine CSF-1 on the feline CSF-1R demonstrates that these recombinant
proteins are identical in their activation.
Fig. 5. Feline monocyte derived and bone marrow derived macrophages. Feline peripheral blood monocytes and bone marrow cells progenitor cells were cultured with
104 Units/ml CSF-1 for 8 days. For both the peripheral blood mononuclear cell (A), and bone marrow cell (B), cultures with rh-CSF-1, cells were adherent, had increased in size
and granularity and divided, thus producing blood monocyte and bone marrow derived macrophages respectively. Cytospin analysis of the blood monocyte derived
macrophages (C) and bone marrow derived macrophages (D) demonstrate that both populations display macrophage-like morphology.
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the bulky aromatic amino acid, Tyr, in humans. This difference
could explain why mouse CSF-1 can bind the pig and cat CSF-1R,
but not the human receptor. Amino acids 78 and 79 of CSF-1 are
Glu and Arg (positive) in mice, Val and Thr in cat (neutral), and
Val and Gln (neutral) in both human and porcine CSF-1. These dif-
ferences could explain the relatively lower efﬁcacy of mouse CSF-1
on the feline CSF-1R.
Both human and mouse IL-34 were also able to activate the fe-
line CSF-1R in vitro; again the mouse ligand was less active. IL-34 ismore species-speciﬁc than CSF-1 as identiﬁed by the reduced
activity of human IL-34 on the mouse CSF-1R [8]. Human IL-34
and CSF-1 were similarly active on the pig CSF-1R [2] but with
the cat receptor the EC50 for human IL-34 was substantially higher
than for CSF-1. Again, the differences between the species probably
reﬂect differences in CSF-1R contact amino acids for IL-34 that may
account for the reduced activity of mouse IL-34 on the cat CSF-1R.
The difference that is most likely to disrupt function is Gln258 (hu-
man and cat) which is substituted with a charged Lys in the mouse
CSF-1R.
Fig. 6. Phagocytic activity of feline monocyte and bone marrow derived macrophages. Cells were cultured for 10 days in rh-CSF-1, prior to the addition of FITC-labelled
Zymosan particles for 1 h. Both cell populations were highly phagocytic and ingested numerous particles of Zymosan after the 1 h incubation. (A) BMC and (B) PBMC.
Fig. 7. Activity of recombinant human and mouse IL-34 on feline CSF-1R expressed
in Ba/F3 cells. An MTT cell viability was used to assess the biological activity of
human and mouse IL-34 on expressed feline CSF-1R. Both human and mouse IL-34
are biologically active on the feline CSF-1R in a dose dependant manner. The EC50
for mouse IL-34 on the feline CSF-1R was approximately 3-fold higher than for
human IL-34.
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combinant CSF-1 has been described previously for human, mouse,
chicken and pig bone marrow cells [7,17,50,52–54]. Culture ofFig. 8. Comparing the activity of human and mouse IL-34 and CSF-1 on expressed feline
human and mouse IL-34 with human and mouse CSF-1. For both human (A) and mouse
human and mouse CSF-1.feline macrophages is a valuable tool to allow the in vitro study
of the effects of drugs, e.g. chemotherapeutic agents, which may
cause immune-suppression or immune-modulation in cats.
Equally, the mechanisms of feline infectious diseases that can in-
fect macrophages, e.g. FIV or mycobacteria, may be further investi-
gated. It will be of interest to compare the response of feline
BMDMs to LPS in a similar fashion to the analysis performed for
mice, human and porcine BMDMs [50,55].
We have demonstrated previously that both recombinant hu-
man and porcine CSF-1 proteins can activate feline and canine
CSF-1Rs using bone marrow aspirates [2]. The primary marrow
cells used in the present study were harvested post-mortem, by re-
peated ﬂushing from the femur. An earlier study Daniel et al. [56]
noted that feline primary bone marrow cultures could be success-
fully maintained without the addition of exogenous CSF-1 due to
the production of CSF-1 by the adherent bone-marrow cell popula-
tion. This is a rather less-reproducible and inefﬁcient approach.
Bone-marrow cells can be frozen and thawed, so that cells pre-
served from a small number of animals can provide a long term re-
source for studies of macrophage biology.
Recent studies investigating the effects of mesenchymal stem
cell (MSC) therapy in rodent models including chronic renal failure
and glomerulonephritis have demonstrated that MSC therapy can
result in beneﬁcial effects [57,58]. In cats, autologous intra-renal
injections of either adipose tissue-derived or bone-marrow-de-
rived mesenchymal stem cells demonstrated modest improve-
ments in glomerular ﬁltration rate (GFR) and serum biochemicalCSF-1R. An MTT cell viability assay was used to compare the biological activity of
(B), IL-34 has demonstrated approximately half the biological activity compared to
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ferentiated cells that can self-renew [60,61]. Due to these proper-
ties, MSCs are being suggested as therapeutic options for a range
of diseases including chronic renal failure in cats [59,62]. CSF-1
mRNA and protein are constitutively expressed [63–65] and, given
the trophic functions, would be candidate mediators of some of the
effects of MSC. Previous studies using non-species-speciﬁc colony
stimulating factors for therapy have been hampered by the devel-
opment of auto-antibodies. For example, the administration of
rhGM-CSF to healthy dogs has been reported to produce neutralis-
ing antibodies after 10–12 days [66]. Similarly, the administration
of rhGM-CSF to cats with FIV triggered neutralising antibodies in
75% of the cats, 35 days after a 2-week treatment protocol [67]. A
practical therapy for cats based upon CSF-1R agonist is likely to in-
volve the production of the species-speciﬁc protein, but this is
costly. For therapeutic trials, our data shows that human and pig
CSF-1 or IL-34 would have similar efﬁcacy and could be considered
for potential therapy. For acute therapy, the generation of neutral-
ising antibodies may not be a signiﬁcant issue.
In conclusion, we have developed an in vitro system for the
study of feline macrophages which will allow further investigation
of macrophage related diseases and the effects of therapy on these
cells. The feline CSF-1R has been cloned and expressed in Ba/F3
cells and used to assess the activity of non-species-speciﬁc CSF-1
and IL-34. This assay also offers the possibility of screening for
antagonists, including blocking antibodies, which might have
applications in inﬂammatory disease and malignancy [1].Acknowledgements
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